Details for Patent: 7,235,567
✉ Email this page to a colleague
Title: | Crystalline polymorph of a bisulfate salt of a thrombin receptor antagonist |
Abstract: | A crystalline polymorph of a bisulfate salt of a thrombin receptor antagonist compound, which exhibits a powder x-ray diffraction profile substantially the same as that shown in FIG. 1, or which exhibits a differential scanning calorimtery profile substantially the same as that shown in FIG. 3, and is represented by the formula for Compound 2: ##STR00001## and processes for preparing Compound 2 are disclosed. Pharmaceutical compositions comprising the polymorph of the bisulfate salt and at least one excipient or carrier, and methods of using the polymorph of Compound 2 to treat a variety of physiological disorders, such as thrombosis, are also disclosed. |
Inventor(s): | Wu; Wenxue (Princeton Junction, NJ) |
Assignee: | Schering Corporation (Kenilworth, NJ) |
Filing Date: | Jan 09, 2004 |
Application Number: | 10/755,066 |
Claims: | 1. A crystalline polymorph Form 1 of Compound 2 of the formula: ##STR00009## that exhibits a powder x-ray diffraction pattern having characteristic peak locations of 11.2, 16.4, 19.2 and 21.0 degrees 2.theta.. 2. The crystalline polymorph of Compound 2 of claim 1 that exhibits a powder x-ray diffraction pattern having characteristic peak locations of 9.9, 11.2, 16.4, 19.2, 21.0, 22.1, 23.7 and 26.7 degrees 2.theta.. 3. The crystalline polymorph of Compound 2 of claim 1 that exhibits a powder x-ray diffraction pattern having characteristic peak locations of 9.9, 11.2, 12.6, 14.5, 16.4, 19.2, 21.0, 22.1, 23.7, 26.7, 28.2 and 30.8 degrees 2.theta.. 4. The crystalline polymorph of Compound 2 of claim 1 that exhibits a powder x-ray diffraction pattern substantially the same as the powder x-ray diffraction pattern shown in FIG 1. 5. A crystalline polymorph Form 1 of Compound 2 of the formula: ##STR00010## that exhibits a differential scanning calorimetry pattern substantially the same as the differential scanning calorimetry pattern shown in FIG. 3. 6. A pharmaceutical composition comprising the crystalline polymorph Form 1 of Compound 2 according to claim 1, and at least one excipient or carrier. 7. A purified form of the crystalline polymorph Form 1 of Compound 2 of claim 1. |